title: Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease.
abstract: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and responses to therapies are highly variable. The aim of this study was to identify the predictors of pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. A total of 127 patients with stable COPD from the Korean Obstructive Lung Disease (KOLD) Cohort, which were prospectively recruited from June 2005 to September 2009, were analyzed retrospectively. The prediction models for the FEV(1), FVC and IC/TLC changes after 3 months of treatment with salmeterol/fluticasone were constructed by using multiple, stepwise, linear regression analysis. The prediction model for the FEV(1) change after 3 months of treatment included wheezing history, pre-bronchodilator FEV(1), post-bronchodilator FEV(1) change and emphysema extent on CT (R = 0.578). The prediction models for the FVC change after 3 months of treatment included pre-bronchodilator FVC, post-bronchodilator FVC change (R = 0.533), and those of IC/ TLC change after 3 months of treatment did pre-bronchodilator IC/TLC and post-bronchodilator FEV(1) change (R = 0.401). Wheezing history, pre-bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD.
authors.affiliation: Department of Pulmonary and Critical Care Medicine, Asthma Center, and Clinical Research Center for Chronic Obstructive Airway Diseases, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil,Seoul, Korea.
authors.forename: Jae Seung
authors.initials: JS
authors.lastname: Lee
authors.forename: Jin Won
authors.initials: JW
authors.lastname: Huh
authors.forename: Eun Jin
authors.initials: EJ
authors.lastname: Chae
authors.forename: Joon Beom
authors.initials: JB
authors.lastname: Seo
authors.forename: Seung Won
authors.initials: SW
authors.lastname: Ra
authors.forename: Ji-Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Eun-Kyung
authors.initials: EK
authors.lastname: Kim
authors.forename: Young Kyung
authors.initials: YK
authors.lastname: Lee
authors.forename: Tae-Hyung
authors.initials: TH
authors.lastname: Kim
authors.forename: Woo Jin
authors.initials: WJ
authors.lastname: Kim
authors.forename: Jin Hwa
authors.initials: JH
authors.lastname: Lee
authors.forename: Sang-Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Sangyeub
authors.initials: S
authors.lastname: Lee
authors.forename: Seong Yong
authors.initials: SY
authors.lastname: Lim
authors.forename: Tae Rim
authors.initials: TR
authors.lastname: Shin
authors.forename: Ho Il
authors.initials: HI
authors.lastname: Yoon
authors.forename: Seung Soo
authors.initials: SS
authors.lastname: Sheen
authors.forename: Yeon-Mok
authors.initials: YM
authors.lastname: Oh
authors.forename: Sang-Do
authors.initials: SD
authors.lastname: Lee
mesh_terms: D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004646:Emphysema; D005260:Female; D000068298:Fluticasone; D006801:Humans; D016014:Linear Models; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D056910:Republic of Korea; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D000068299:Salmeterol Xinafoate; D015898:Tomography Scanners, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol